Evidence map›Paper›PMID 32703005›Full record

ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

SPOT GRADE II: Clinical Validation of a New Method for Reproducibly Quantifying Surgical Wound Bleeding: Prospective, Multicenter, Multispecialty, Single-Arm Study.

Daniel J Del Gaizo, William D Spotnitz, Rachel W Hoffman, Mark Christopher Hermann, Linda S Sher, Russell H Spotnitz, Yuri S Genyk, Ian J Schorn, Daniel L Gillen, Bobby L White and 2 more

Abstract readMulticenter Study
In one paragraph

Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Efficacy of AriClot™ hemostatic powder versus standard pressure dressing for bleeding control in civilian penetrating trauma: A randomized controlled trial.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2026
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Daniel J Del GaizoDepartment of Orthopedics, University of North Carolina, Chapel Hill, NC, USA.
William D SpotnitzDepartment of Surgery, University of Virginia, Charlottesville, VA, USA.ORCID https://orcid.org/0000-0002-1779-1457
Rachel W HoffmanBiom'Up France, SAS, Saint-Priest, France.
Mark Christopher HermannSpectrum Medical, Danville, VA, USA.
Linda S SherDepartment of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Russell H SpotnitzBiom'Up France, SAS, Saint-Priest, France.
Yuri S GenykDepartment of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0001-9552-3995
Ian J SchornBiom'Up France, SAS, Saint-Priest, France.
Daniel L GillenDepartment of Statistics, University of California, Irvine, CA, USA.
Bobby L WhiteSpectrum Medical, Danville, VA, USA.
Bruce G MillerDepartment of Orthopedics, University of North Carolina, Chapel Hill, NC, USA.
Roberto J MansonBiom'Up France, SAS, Saint-Priest, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SPOT GRADE (SG), a Surface Bleeding Severity Scale, is a unique visual method for assessing bleeding severity based on quantitative determinations of blood flow. This study assessed the reliability of the SG scale in a clinical setting and collected initial data on the safety and efficacy of HEMOBLAST Bellows (HB), a hemostatic agent, in abdominal and orthopedic operations. Twenty-seven patients were enrolled across 3 centers and received the investigational device. Bleeding severity and hemostasis were independently assessed by 2 surgical investigators at baseline and at 3, 6, and 10 minutes after application of HB and compared for agreement. The mean paired κ statistic for assignment of SG scores was .7754. The mean paired κ statistics for determining eligibility for participation in the trial based on bleeding severity and the mean paired κ statistics determining the presence of hemostasis were .9301 and .9301, respectively. The proportion of patients achieving hemostasis within 3, 6, and 10 minutes of HB application were 50.0%, 79.2%, and 91.7%, respectively. There were no unanticipated adverse device effects and one possible serious adverse device effect, as determined by the Independent Data Monitoring Committee (IDMC). The reliability of the SG scale was validated in a clinical setting. Initial data on the safety and efficacy of HB in abdominal and orthopedic operations were collected, and there were no concerns raised by the investigators or the IDMC.

Indexed as

AgedBlood Loss, SurgicalFemaleHumansMaleMiddle AgedProspective StudiesSurgical WoundHEMOBLAST BellowsSPOT GRADESurface Bleeding Severity Scaletarget bleeding site

Identifiers

PMID32703005
PMCPMC7383655

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.